Drugs Made In America Acquisition (DMAAU) Equity Ratio (2024 - 2025)

Drugs Made In America Acquisition (DMAAU) reported Equity Ratio of 0.03 for Q4 2025, up 93.19% on a YoY basis from 0.02 in Q4 2024, and up 1.82% quarter-over-quarter from 0.03 in Q3 2025.

Drugs Made In America Acquisition (DMAAU) Equity Ratio (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Equity Ratio for 2 years, with the latest figure at 0.03 in Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 93.19% year-over-year to 0.03; the trailing twelve-month figure through Dec 2025 stood at 0.03 (up 93.19% YoY), and the FY2025 full-year result was 0.03, up 93.19% from the prior year.
  • Equity Ratio for Q4 2025 stood at 0.03, up from 0.03 in the prior quarter.
  • The five-year high for Equity Ratio was 0.03 in Q4 2025, with the low at 0.44 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -0.03
2 Berto Acquisition 312.46 Mn 312.46 Mn - -0.04
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -0.04
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - -0.05
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -0.04
6 WEN Acquisition 309.15 Mn 309.15 Mn - -0.04
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - -0.03
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - -0.04
9 BTC Development 262.16 Mn 262.16 Mn - -0.04
10 Drugs Made In America Acquisition - - - -0.03

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.03
Sep 30, 2025 -0.03
Jun 30, 2025 -0.03
Mar 31, 2025 -0.03
Dec 31, 2024 -0.44